Veru Inc (VERU) Actualités

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025

MIAMI, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage...

Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

-- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss...

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

MIAMI, FL, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage...

Form EFFECT - Notice of Effectiveness

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form POS AM - Post-Effective amendments for registration statement